Semaglutide vs Liraglutide: Weekly vs Daily GLP-1 Comparison
Semaglutide (Ozempic/Wegovy) is a once-weekly GLP-1 receptor agonist with a ~7-day half-life that achieves approximately 15-17% body weight loss in STEP trials and demonstrated a 20% MACE reduction in the SELECT cardiovascular outcomes trial. Liraglutide (Victoza/Saxenda) is a once-daily GLP-1 receptor agonist with a ~13-hour half-life that achieves approximately 8% weight loss in SCALE trials with proven cardiovascular benefits in the LEADER trial. Both are FDA-approved for type 2 diabetes and obesity but differ in potency, dosing convenience, and clinical data depth.
Side-by-Side Comparison
| Parameter | Semaglutide | Liraglutide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist (C18 acylated) | GLP-1 receptor agonist (C16 acylated) |
| Evidence Grade | A+ | A+ |
| Key Trials | STEP 1-5, SUSTAIN 1-10, SELECT | SCALE 1-4, LEADER, LIRA-series |
| Max Weight Loss | ~16.9% at 68 weeks (STEP-1) | ~8.0% at 56 weeks (SCALE) |
| Route | SC injection (weekly) or oral (daily) | SC injection (daily) |
| Typical Dose | 0.25 - 2.4 mg weekly (SC) | 0.6 - 3.0 mg daily |
| Half-Life | ~7 days (injectable) | ~13 hours |
| CV Outcomes | 20% MACE reduction (SELECT) | 13% MACE reduction (LEADER) |
| FDA Status | FDA-approved (T2D + obesity) | FDA-approved (T2D + obesity) |
| Oral Option | Yes (Rybelsus 3/7/14 mg daily) | No |
| Cost (research grade) | $$$ | $$ |
Semaglutide: Pros & Cons
Advantages
- Superior weight loss (~17% vs ~8%)
- Once-weekly dosing convenience
- Oral formulation available (Rybelsus)
- 20% MACE reduction in SELECT trial
- Most-studied incretin therapy in history
- HbA1c reduction superior to liraglutide
Considerations
- Higher cost than liraglutide
- GI side effects common during titration
- Shorter market history than liraglutide
- Longer titration period to full dose
- Weight regain after discontinuation
Liraglutide: Pros & Cons
Advantages
- Longest market history among GLP-1 agonists
- Proven cardiovascular safety (LEADER trial)
- Extensive long-term safety data
- Lower cost than semaglutide
- More flexible dose titration
- Pediatric obesity approval (ages 12+)
Considerations
- Daily injection required (less convenient)
- Lower weight loss efficacy than semaglutide
- No oral formulation
- Shorter half-life means less sustained receptor activation
- Being superseded by newer GLP-1 agents in guidelines
Which Is Right for Your Research?
Decision Guide
Choose semaglutide research if: You need the maximum weight loss efficacy, weekly dosing convenience, or the most comprehensive evidence base including cardiovascular outcomes in non-diabetic obesity (SELECT). Semaglutide is the current gold standard GLP-1 agonist for both efficacy and data depth. The STEP-8 head-to-head trial directly confirmed superiority over liraglutide.
Choose liraglutide research if: You need the longest-established safety profile, lower cost, pediatric data (ages 12+), or daily dose flexibility. Liraglutide's extensive post-marketing safety data spanning over a decade provides the most mature safety signal of any GLP-1 agonist. It remains useful as an active comparator in clinical trials.
Frequently Asked Questions
Yes, the STEP-8 head-to-head trial confirmed semaglutide's superiority with 15.8% vs 6.4% weight loss at 68 weeks. Semaglutide's longer half-life provides more sustained GLP-1 receptor activation, translating to greater appetite suppression and metabolic effects.
Semaglutide has a C18 fatty acid chain and amino acid substitutions increasing albumin binding and DPP-4 resistance, giving a ~7-day half-life. Liraglutide has a C16 fatty acid with ~13-hour half-life. Both are modified from native GLP-1 which has a 2-minute half-life.
Both demonstrate CV benefits. SELECT showed semaglutide reduces MACE by 20% in obese patients without diabetes. LEADER showed liraglutide reduces MACE by 13% in T2D patients. SELECT is notable as the first to show CV benefit in obesity without diabetes.
Related Protocol Guides
Compare More
Verified Research Suppliers
- ★ LiveWell Peptides — Official Sponsor • cGMP Certified Paid partnership
- Core Peptides — Third-party tested
- Limitless Life Nootropics — Broad catalog
- Biotech Peptides — USA-based
- Amino Asylum — Budget-friendly
© 2026 Path to Peptides™. For research and educational purposes only. Not medical advice.
Some links on this site may earn a commission at no cost to you.